Janux Therapeutics (JANX) closed at $11.50 on November 12, 2026, down 7.2% from the previous close, on volume of 1,041,142 shares (30-day average 941,382).
Data as of November 12, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 29, 2026 | Call Spread | 21-Jan-2817.5 : 30 C | 260 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 12, 2026. See the 10 largest for 30, 60 and 90 days
Analysts’ Top Healthcare Picks: enGene Holdings (ENGN), Janux Therapeutics Inc (JANX)
TipRanks (Thu, 12-Nov 7:30 AM ET)
Stifel Nicolaus Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX)
TipRanks (Tue, 10-Nov 8:26 AM ET)
Piper Sandler Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX)
TipRanks (Tue, 10-Nov 8:06 AM ET)
UBS Reaffirms Their Hold Rating on Janux Therapeutics Inc (JANX)
TipRanks (Tue, 10-Nov 7:35 AM ET)
Business Wire (Mon, 9-Nov 8:30 AM ET)
Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
Business Wire (Thu, 5-Nov 4:02 PM ET)
Business Wire (Mon, 2-Nov 4:02 PM ET)
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
Business Wire (Mon, 14-Sep 8:00 AM ET)
Market Chameleon (Thu, 22-Jan 6:21 AM ET)
Market Chameleon (Thu, 22-Jan 2:35 AM ET)
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Janux Therapeutics trades on the NASDAQ stock market under the symbol JANX.
As of November 13, 2026, JANX stock price declined to $11.44 with 14,773 million shares trading.
JANX has a beta of 1.38, meaning it tends to be more sensitive to market movements. JANX has a correlation of 0.04 to the broad based SPY ETF.
JANX has a market cap of $699.40 million. This is considered a Small Cap stock.
Last quarter Janux Therapeutics reported $9 million in Revenue and -$.34 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.14.
In the last 3 years, JANX traded as high as $71.71 and as low as $5.81.
The top ETF exchange traded funds that JANX belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWN.
JANX has underperformed the market in the last year with a price return of -59.9% while the SPY ETF gained +12.3%. JANX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -31.4% and -35.8%, respectively, while the SPY returned -1.4% and -1.2%, respectively.
JANX support price is $11.09 and resistance is $11.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JANX shares will trade within this expected range on the day.
